Abstract
The bee venom is used for treating a wide variety of conditions from acute tendonitis to chronic back pain to rheumatoid arthritis (RA). The major treatment is gene therapy or recombinant DNA vaccines involved in targeting multiple antigenic components to direct and empower the immune system to protect the host from infection. Limitations of therapy for the treatment of patients suffering from various adverse reaction and contraindications are always experienced. Antigenic epitopes on melittin protein of Apis dorsata are important determinants of protection against rheumatoid arthritis. As our knowledge of the immune responses to a protein antigen progressed, it became clear that the whole protein is not necessary for raising the immune response, but small segments as 4-AILKVLSTGLPALIS-18 of protein called the antigenic determinants or the epitopes, are sufficient for eliciting the desired immune response. Immunization cassettes should be capable of immunizing broad immunity against both humoral and cellular epitopes, thus giving vaccines the maximum ability to deal with A. dorsata immune escape against rheumatoid arthritis.
Keywords: Antigenic epitope, secondary structure, hydrophobicity, hydrophilicity
Current Proteomics
Title: Antigenicity Prediction in Melittin: Possibilities of in Drug Development from Apis dorsata
Volume: 4 Issue: 2
Author(s): V. S. Gomase and S. S. Changbhale
Affiliation:
Keywords: Antigenic epitope, secondary structure, hydrophobicity, hydrophilicity
Abstract: The bee venom is used for treating a wide variety of conditions from acute tendonitis to chronic back pain to rheumatoid arthritis (RA). The major treatment is gene therapy or recombinant DNA vaccines involved in targeting multiple antigenic components to direct and empower the immune system to protect the host from infection. Limitations of therapy for the treatment of patients suffering from various adverse reaction and contraindications are always experienced. Antigenic epitopes on melittin protein of Apis dorsata are important determinants of protection against rheumatoid arthritis. As our knowledge of the immune responses to a protein antigen progressed, it became clear that the whole protein is not necessary for raising the immune response, but small segments as 4-AILKVLSTGLPALIS-18 of protein called the antigenic determinants or the epitopes, are sufficient for eliciting the desired immune response. Immunization cassettes should be capable of immunizing broad immunity against both humoral and cellular epitopes, thus giving vaccines the maximum ability to deal with A. dorsata immune escape against rheumatoid arthritis.
Export Options
About this article
Cite this article as:
Gomase S. V. and Changbhale S. S., Antigenicity Prediction in Melittin: Possibilities of in Drug Development from Apis dorsata, Current Proteomics 2007; 4 (2) . https://dx.doi.org/10.2174/157016407782194639
DOI https://dx.doi.org/10.2174/157016407782194639 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Engineered Inorganic Nanoparticles for Drug Delivery Applications
Current Drug Metabolism Permeation Efficacy of a Transdermal Vehicle with Steroidal Hormones and Nonsteroidal Anti-inflammatory Agents as Model Drugs
Current Drug Delivery A Review of the Treatment of Psoriasis with Infliximab
Reviews on Recent Clinical Trials Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Computational Approaches for the Identification and Optimization of Src Family Kinases Inhibitors
Current Medicinal Chemistry Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Biologic Therapy in Inflammatory and Immunomediated Arthritis: Safety Profile
Current Drug Safety Co-opting Functions of Cholinesterases in Neural, Limb and Stem Cell Development
Protein & Peptide Letters Development of Infection and Inflammation Targeting Compounds
Current Radiopharmaceuticals The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE
Current Topics in Medicinal Chemistry Suppression of NF-κB Activation By Gentian Violet Promotes Osteoblastogenesis and Suppresses Osteoclastogenesis
Current Molecular Medicine Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Editorial from Guest Editor [Hot Topic:Animal Venoms: From Deadly Arsenals (Toxins) to Therapeutic Drug Candidates (Guest Editor: Jean-Marc Sabatier)]
Inflammation & Allergy - Drug Targets (Discontinued) Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Trends in Nanotechnology Patents Applied to the Health Sector
Recent Patents on Nanotechnology Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pharmacotranscriptomic Biomarkers in Glucocorticoid Treatment of Pediatric Inflammatory Bowel Disease
Current Medicinal Chemistry Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Immune Cell-derived Vesicles: Modulators and Mediators of Inflammation
Current Pharmaceutical Design The Relevance of Supplemental Vitamin D in Malignancies
Anti-Cancer Agents in Medicinal Chemistry